What Is NAD+ (Nicotinamide Adenine Dinucleotide)?

What NAD+ is

NAD+ accepts and donates electrons in redox reactions (the NAD+/NADH pair), which is central to how cells make ATP. It is also a substrate for non-redox enzymes, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and NAD+ glycohydrolases such as CD38. Sirtuins help regulate gene expression and mitochondrial function. PARPs use NAD+ during DNA-repair signaling (Covarrubias et al., Nat Rev Mol Cell Biol, 2021, PMID: 33353981).

Reviews describe a decline in tissue NAD+ with age in animals and, in some human tissues. The same papers are careful on the next point: it is still being worked out how fully that decline explains aging in people, how to restore NAD+ safely, and whether restoration will produce clinically meaningful benefits in aging humans.

YourHealthRx lists NAD+ as a longevity and cellular-support option in a nasal-spray form and in injectable vials. Listing it is not a guarantee that it is appropriate, available in your state, or that a prescription will be issued.

NAD+ vs NMN vs NR

This is the search most people actually run.

NAD+ is the coenzyme itself. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors. Cells can also make NAD+ from niacin, nicotinamide, and, in some tissues, tryptophan. Intact NAD+ is not freely cell-permeable in the way a simple vitamin is, which is one reason oral NMN and NR became research and supplement products (PMID: 33353981).

Those products are not interchangeable with compounded NAD+.

• Oral NMN and NR are typically sold as dietary supplements. They are not FDA-approved drugs. In September 2025, FDA stated that NMN is not excluded from the dietary-supplement definition. That is a supplement-law question, not a finding that NMN treats aging.
• Compounded NAD+ is a prescription preparation made for an identified patient when a clinician decides that is appropriate. Compounded medications are not FDA-approved.

The useful distinction is access path and route, not a ranking of which product is “stronger.” Oral precursors, nasal spray, injectable vials, and clinic IV infusions are different conversations. A clinician can sort which, if any, belongs with your history and goals.

Is NAD+ FDA-approved?

No. There is no FDA-approved NAD+ drug product for anti-aging, energy, cognition, or general longevity.

Compounding is a separate framework. FDA’s list of bulk drug substances nominated for compounding under section 503A includes nicotinamide adenine dinucleotide (NAD) in Category 1, alongside NADH. Category 1 means the substance is nominated and under evaluation. It is not FDA approval, and it is not a final decision that NAD belongs on the 503A bulks list. Under FDA’s interim 503A policy, a state-licensed pharmacy may compound a patient-specific prescription from a Category 1 bulk substance when the other conditions of that policy are met (FDA 503A nominated bulks list).

503B outsourcing facilities are a different lane: NAD+ does not appear on the 503B bulks list (FDA warning letter, GenoGenix LLC, Jan 20, 2026). That is a facility-category point, not a verdict on NAD+ as a molecule. It is why pharmacy pathway and clinician review belong next to “can I get NAD+?”

What the evidence actually says

The mechanistic story is the strongest part. NAD+ is required for redox metabolism and for sirtuin and PARP activity. In rodent models, restoring NAD+ with precursors has been studied for metabolic, muscle, and neurodegenerative endpoints (PMID: 33353981).

Human data are narrower. Oral NR and NMN trials have shown that those precursors can raise NAD+ measurements in defined groups. Clinical outcomes such as weight, insulin sensitivity, or cognition have been mixed or still early, and most studies are small or short.

Direct NAD+ administration is thinner still. A 2019 pilot infused NAD+ intravenously and tracked the plasma and urine metabolome. That study describes pharmacokinetics, not anti-aging outcomes (Grant et al., Front Aging Neurosci, 2019). Infusion-related discomfort (nausea, flushing, cramping) is commonly reported in IV-clinic settings. Those reports are not a dosing guide.

There are no large randomized trials showing that compounded NAD+ reverses aging or restores energy on a clock. “May support cellular-energy and mitochondrial-function goals” is a different sentence from “treats aging.”

Nasal spray, injectable, and IV are not the same conversation

Route changes delivery, monitoring, and compounding analysis. It does not rank one form as a consolation prize.

YourHealthRx partner workflows discuss a nasal-spray NAD+ option and injectable options in 5 ml and 10 ml vials. Clinic-style IV NAD+ is a different setting: a timed infusion under on-site observation, often marketed for wellness rather than a defined labeled use.

A clinician matches route to the person: medical history, medications, whether sterile compounding is involved, and whether the goal is even an NAD+ conversation. Price is not the decision. YourHealthRx currently lists NAD+ nasal spray from $150/mo and injectable vials from $210/mo. Those are “as low as” listed prices. Prescriptions are not guaranteed.

If low energy or “recovery” is new, sudden, or tied to sleep, mood, a new medication, or unexplained weight change, those facts belong in the intake. They can change whether NAD+ is the next step, or whether labs and a different workup come first.

What a clinician reviews

Longevity products are easy to shop. The screening is still medical.

A clinician typically looks at current medications, liver and kidney context, cardiovascular history, pregnancy or nursing, and whether symptoms have a more direct explanation. Sterile injectable products add a quality conversation: pharmacy pathway, identity and potency, and storage. Food-grade bulk is not a sterile-injection starting material.

NAD+ is not a substitute for sleep, nutrition, or treatment of a diagnosed disease. Follow-up matters the same way it does on other pathways: how you feel, tolerability, whether labs were part of the baseline, and whether the original goal still fits.

FAQ

Is NAD+ FDA-approved?

No. There is no FDA-approved NAD+ product for anti-aging or general wellness. Compounded NAD+ is not the same as an approved drug.

Is NAD+ the same as NMN or NR?

No. NMN and NR are precursors. NAD+ is the coenzyme. Oral supplements and compounded NAD+ sit on different regulatory tracks.

Is compounded NAD+ legal?

Patient-specific 503A compounding of nominated Category 1 bulk substances may fall under FDA’s interim policy when the other legal conditions are met. That is not FDA approval, and 503B office-use compounding is a different analysis. A licensed clinician and a licensed pharmacy have to be in the loop.

Will it reverse aging?

No honest article can say that. The biology is being studied. Human outcome evidence for compounded NAD+ is limited.